Short-term 1,25-dihydroxyvitamin D3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis

J. E. Zerwekh, K. Sakhaee, C. Y C Pak

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

In order to evaluate whether 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] could increase the serum concentration of osteocalcin (BGP) in patients with post-menopausal osteoporosis, we administered 2 μg/d of 1,25(OH)2D3 to 14 patients with biopsy proven osteoporosis for two weeks. An additional 13 age and sex-matched patients with osteoporosis received no drug and served as the control. Administration of 1,25(OH)2D3 significantly increased the serum concentration of 1,25(OH)2D from 31 ± 2 SE to 56 ± 5 pg/ml (p < 0.01). Commensurate with the rise in 1,25(OH)2D was a significant increase in BGP from 3.9 ± 0.6 to 6.4 ± 0.9 ng/ml (p < 0.001). There were no significant changes for these parameters in the control group. It is concluded that short term 1,25(OH)2D3 administration is effective in raising BGP concentrations in patients with post-menopausal osteoporosis.

Original languageEnglish (US)
Pages (from-to)615-617
Number of pages3
JournalJournal of Clinical Endocrinology and Metabolism
Volume60
Issue number3
StatePublished - 1985

Fingerprint

Postmenopausal Osteoporosis
Calcitriol
Osteocalcin
Biopsy
Serum
Osteoporosis
Pharmaceutical Preparations
Control Groups

ASJC Scopus subject areas

  • Biochemistry

Cite this

@article{e1b2105cf0c7415fa8d2919bd0e5c96d,
title = "Short-term 1,25-dihydroxyvitamin D3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis",
abstract = "In order to evaluate whether 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] could increase the serum concentration of osteocalcin (BGP) in patients with post-menopausal osteoporosis, we administered 2 μg/d of 1,25(OH)2D3 to 14 patients with biopsy proven osteoporosis for two weeks. An additional 13 age and sex-matched patients with osteoporosis received no drug and served as the control. Administration of 1,25(OH)2D3 significantly increased the serum concentration of 1,25(OH)2D from 31 ± 2 SE to 56 ± 5 pg/ml (p < 0.01). Commensurate with the rise in 1,25(OH)2D was a significant increase in BGP from 3.9 ± 0.6 to 6.4 ± 0.9 ng/ml (p < 0.001). There were no significant changes for these parameters in the control group. It is concluded that short term 1,25(OH)2D3 administration is effective in raising BGP concentrations in patients with post-menopausal osteoporosis.",
author = "Zerwekh, {J. E.} and K. Sakhaee and Pak, {C. Y C}",
year = "1985",
language = "English (US)",
volume = "60",
pages = "615--617",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Short-term 1,25-dihydroxyvitamin D3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis

AU - Zerwekh, J. E.

AU - Sakhaee, K.

AU - Pak, C. Y C

PY - 1985

Y1 - 1985

N2 - In order to evaluate whether 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] could increase the serum concentration of osteocalcin (BGP) in patients with post-menopausal osteoporosis, we administered 2 μg/d of 1,25(OH)2D3 to 14 patients with biopsy proven osteoporosis for two weeks. An additional 13 age and sex-matched patients with osteoporosis received no drug and served as the control. Administration of 1,25(OH)2D3 significantly increased the serum concentration of 1,25(OH)2D from 31 ± 2 SE to 56 ± 5 pg/ml (p < 0.01). Commensurate with the rise in 1,25(OH)2D was a significant increase in BGP from 3.9 ± 0.6 to 6.4 ± 0.9 ng/ml (p < 0.001). There were no significant changes for these parameters in the control group. It is concluded that short term 1,25(OH)2D3 administration is effective in raising BGP concentrations in patients with post-menopausal osteoporosis.

AB - In order to evaluate whether 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] could increase the serum concentration of osteocalcin (BGP) in patients with post-menopausal osteoporosis, we administered 2 μg/d of 1,25(OH)2D3 to 14 patients with biopsy proven osteoporosis for two weeks. An additional 13 age and sex-matched patients with osteoporosis received no drug and served as the control. Administration of 1,25(OH)2D3 significantly increased the serum concentration of 1,25(OH)2D from 31 ± 2 SE to 56 ± 5 pg/ml (p < 0.01). Commensurate with the rise in 1,25(OH)2D was a significant increase in BGP from 3.9 ± 0.6 to 6.4 ± 0.9 ng/ml (p < 0.001). There were no significant changes for these parameters in the control group. It is concluded that short term 1,25(OH)2D3 administration is effective in raising BGP concentrations in patients with post-menopausal osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=0022001577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022001577&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 615

EP - 617

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -